TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics (NASDAQ: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 4:55 p.m. Eastern Time at the Marriott Marquis in New York. Investors and interested parties can access the presentation webcast through the "Events and Presentations" section on TScan's website at ir.tscan.com, with the replay remaining available for 90 days after the event.
TScan Therapeutics (NASDAQ: TCRX), un'azienda biotecnologica in fase clinica che sviluppa terapie con cellule T ingegnerizzate con TCR per il trattamento del cancro, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. La presentazione è prevista per il 4 giugno 2025 alle 16:55 ora della costa est presso il Marriott Marquis di New York. Investitori e interessati potranno seguire la presentazione in webcast nella sezione "Events and Presentations" sul sito di TScan all'indirizzo ir.tscan.com, con la replica disponibile per 90 giorni dopo l'evento.
TScan Therapeutics (NASDAQ: TCRX), una empresa biotecnológica en etapa clínica que desarrolla terapias con células T modificadas con TCR para el tratamiento del cáncer, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. La presentación está programada para el 4 de junio de 2025 a las 4:55 p.m., hora del Este, en el Marriott Marquis de Nueva York. Los inversores y partes interesadas podrán acceder a la transmisión en vivo a través de la sección "Events and Presentations" en el sitio web de TScan en ir.tscan.com, con la repetición disponible durante 90 días después del evento.
TScan Therapeutics (NASDAQ: TCRX)는 암 치료를 위한 TCR 유전자 조작 T 세포 치료제를 개발하는 임상 단계 바이오테크 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 발표는 2025년 6월 4일 오후 4시 55분(동부 표준시)에 뉴욕의 Marriott Marquis에서 진행됩니다. 투자자 및 관심 있는 분들은 TScan 웹사이트 ir.tscan.com의 "Events and Presentations" 섹션을 통해 웹캐스트 발표를 시청할 수 있으며, 이벤트 종료 후 90일 동안 다시보기 서비스가 제공됩니다.
TScan Therapeutics (NASDAQ : TCRX), une entreprise biotechnologique en phase clinique développant des thérapies cellulaires TCR modifiées pour le traitement du cancer, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. La présentation est prévue pour le 4 juin 2025 à 16h55, heure de l'Est, au Marriott Marquis de New York. Les investisseurs et parties intéressées peuvent accéder à la diffusion en direct via la section "Events and Presentations" du site web de TScan à ir.tscan.com, avec un replay disponible pendant 90 jours après l'événement.
TScan Therapeutics (NASDAQ: TCRX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das TCR-entwickelte T-Zell-Therapien zur Krebsbehandlung entwickelt, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Die Präsentation findet am 4. Juni 2025 um 16:55 Uhr Eastern Time im Marriott Marquis in New York statt. Investoren und Interessierte können die Präsentation über den Webcast im Bereich "Events and Presentations" auf der TScan-Website unter ir.tscan.com verfolgen. Die Wiedergabe ist für 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time.
A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When is TScan Therapeutics (TCRX) presenting at the Jefferies Healthcare Conference 2025?
Where can I watch TScan Therapeutics' (TCRX) Jefferies conference presentation?
What type of therapies is TScan Therapeutics (TCRX) developing?
Where will the Jefferies Global Healthcare Conference 2025 be held?
